Oxford, UK, 21 January 2021 – Argonaut Therapeutics, a leading developer of novel cancer agents, announced the appointment of Dr Chan Hee Park to its Board of Directors, representing key investor, JW Pharmaceutical Corporation. Dr Park is the Chief Technological…
Oxford, UK, 20 January 2021 – Celleron Therapeutics, the Oxford-based UK company developing novel medicines to treat cancer, today announced that with its Chinese partner, Nuance Biotech Ltd, the company has received approval from the Chinese Center for Drug Evaluation for…
Oxford, November 30, 2020 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announces the formation of a new spin out, SynOx Therapeutics, as a vehicle for the continued development of emactuzumab as an effective treatment for…
Oxford, UK, 24 September 2020 – Professor David Kerr, The Chief Medical Officer of Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients, today attended and presented remotely at the opening ceremony of BIO-FORUM 2020…
Oxford, 12th August 2020 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the signing of a licensing agreement with Roche providing Celleron exclusive world-wide rights for the clinical development, manufacturing and commercialization of emactuzumab.…
Oxford, UK, 1 August 2020 – Argonaut Therapeutics, a leading developer of novel cancer agents, announced the appointment of Mr Nick Dixon-Clegg to its Board of Directors, representing key investor, Oxford Sciences Innovation. Nick is a Principal at OSI and…
Oxford, UK / Sichuan, China, 15 May 2020 Today marks the launch of the University of Oxford-Sichuan University Huaxi Joint Centre for Gastrointestinal Cancer, led by Prof. David Kerr (Radcliffe Department of Medicine, University of Oxford) and Prof. Li Yang…
Oxford, UK, 2nd March 2020 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced that its partner in China, Nuance Biotech Ltd., initiated a Phase Ib/II study in Hong Kong to test CXD101 in patients…
Lack of colitis side effect with CXD101 and nivolumab combination therapy in CAROSELL Phase II clinical trial of MSS CRC patients Oxford, UK, 14 Jan 2020 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, announced today…
Oxford, UK,21 October 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients, today announced that it has appointed James Noble to join its Board as Non-Executive Director. James Noble MA FCA has held…